Leg-saving cell therapy

Jason Napodano submits: Positive Top-Line RESTORE-CLI Data

By Jason Napodano: Full Data From RESTORE-CLI Presented at AHA On November 14, 2011, Aastrom Bio reported the final analysis from the phase 2b RESTORE-CLI trial. The RESTORE-CLI clinical trial assessed the safety and ability of ixmyelocel-T, Aastrom's expanded, bone marrow-derived cellular therapy, to restore damaged tissue in a lower extremity affected by critical limb ischemia (CLI). The results include the final analysis from all 86 randomized patients.

By Jason Napodano: By Jason Napodano, CFA

Shlomi Cohen submits: Pluristem Therapeutics Ltd.

EP Vantage submits:Aastrom Biosciences’ stem-cell therapy for treating critical limb ischaemia (CLI) had a happier outcome then its gene therapy competitor Vical in that the stem-cell approach reported positive clinical data last week (Gene therapy suffers another blow as Temusi crashes out).

By Henry McCusker: Valuation versus Share Pricing Aastrom Biosciences (ASTM) develops autologous cellular therapies for the treatment of severe and chronic cardiovascular diseases.

By M.E. Garza: Shares of Aastrom Biosciences (ASTM) have been on the slide since mid-November when the company announced that its cell therapy Ixmyelocel-T proved safe in a mid-stage clinical trial and helped delay some symptoms of critical limb ischemia, a severe form of peripheral arterial disease, in patients who have no real alternatives.

M.E. Garza submits: Aastrom Biosciences, Inc. (ASTM) announced that the final analysis of data from its RESTORE-CLI trial showed that the trial met its primary safety and efficacy endpoints, demonstrating a statistically significant improvement in the time to first occurrence of treatment failure at 12 months.